Matinas BioPharma Holdings Croissance future

Future contrôle des critères 0/6

Matinas BioPharma Holdings devrait augmenter ses bénéfices et ses revenus de 71.9% et de 93.6% par an respectivement, tandis que le BPA devrait croître de croître de 72.5% par an.

Informations clés

71.9%

Taux de croissance des bénéfices

72.5%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	93.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	19 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Feb 23

Prévisions de croissance des bénéfices et des revenus

NYSEAM:MTNB - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-31	N/A	N/A	2
12/31/2025	N/A	-19	N/A	N/A	2
12/31/2024	N/A	-20	N/A	N/A	2
9/30/2024	N/A	-21	-17	-17	N/A
6/30/2024	N/A	-23	-18	-18	N/A
3/31/2024	N/A	-23	-17	-17	N/A
12/31/2023	1	-23	-15	-15	N/A
9/30/2023	2	-21	-15	-15	N/A
6/30/2023	3	-21	-16	-16	N/A
3/31/2023	4	-21	-19	-18	N/A
12/31/2022	3	-21	-20	-19	N/A
9/30/2022	2	-24	-20	-19	N/A
6/30/2022	1	-25	-20	-20	N/A
3/31/2022	0	-24	-16	-15	N/A
12/31/2021	0	-24	-15	-15	N/A
9/30/2021	0	-24	-16	-16	N/A
6/30/2021	0	-22	-15	-15	N/A
3/31/2021	0	-23	-17	-17	N/A
12/31/2020	0	-23	-17	-17	N/A
9/30/2020	0	-22	-18	-18	N/A
6/30/2020	N/A	-21	-17	-17	N/A
3/31/2020	0	-19	-16	-16	N/A
12/31/2019	0	-18	-14	-14	N/A
9/30/2019	0	-16	-12	-12	N/A
6/30/2019	0	-15	-11	-10	N/A
3/31/2019	0	-15	-11	-11	N/A
12/31/2018	0	-15	-11	-10	N/A
9/30/2018	0	-15	-10	-10	N/A
6/30/2018	0	-15	N/A	-10	N/A
3/31/2018	0	-16	N/A	-11	N/A
12/31/2017	0	-33	N/A	-11	N/A
9/30/2017	0	-31	N/A	-12	N/A
6/30/2017	0	-34	N/A	-10	N/A
3/31/2017	0	-31	N/A	-8	N/A
12/31/2016	N/A	-12	N/A	-6	N/A
9/30/2016	N/A	-12	N/A	-5	N/A
6/30/2016	0	-8	N/A	-6	N/A
3/31/2016	0	-9	N/A	-7	N/A
12/31/2015	0	-9	N/A	-8	N/A
9/30/2015	0	-10	N/A	-9	N/A
6/30/2015	0	-11	N/A	-9	N/A
3/31/2015	0	-11	N/A	-8	N/A
12/31/2014	N/A	-10	N/A	-8	N/A
9/30/2014	N/A	-9	N/A	-7	N/A
6/30/2014	N/A	-8	N/A	-6	N/A
3/31/2014	N/A	-6	N/A	-5	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MTNB devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: MTNB devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: MTNB devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: MTNB ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: MTNB ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MTNB devrait être élevé dans 3 ans

Matinas BioPharma Holdings Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

No longer forecast to breakeven

Consensus revenue estimates fall by 90%

Consensus revenue estimates fall by 46%

Forecast to breakeven in 2025

Price target decreased to US$2.75

Consensus forecasts updated

Recent updates

New major risk - Market cap size

Matinas BioPharma Holdings, Inc. Announces Executive Changes

New minor risk - Share price stability

Matinas BioPharma Holdings, Inc. to Report Q2, 2024 Results on Aug 14, 2024

Matinas Biopharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program

New major risk - Revenue and earnings growth

Matinas BioPharma Holdings, Inc. to Report Q1, 2024 Results on May 09, 2024

New minor risk - Shareholder dilution

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

New major risk - Share price stability

Matinas BioPharma Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Matinas Biopharma Announces Positive in Vivo Safety Data with Its Oral Lnc-Docetaxel Formulation

Matinas BioPharma Holdings, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

Matinas Biopharma Provides Positive Outcomes Update on the Mat2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

Matinas BioPharma Holdings, Inc. Demonstrates in Vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

Matinas Biopharma Holdings, Inc. Provides Update to Mat2203 Regulatory and Development Pathway Following Feedback from FDA

Third quarter 2023 earnings released: US$0.028 loss per share (vs US$0.025 loss in 3Q 2022)

Matinas Biopharma Holdings, Inc. Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model

Matinas BioPharma Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Matinas BioPharma Holdings, Inc. Announces Complete Clinical Resolution of a Patient’s Recurrent Hemorrhagic Cystitis Due to Candida krusei Following Treatment with MAT2203

No longer forecast to breakeven

Insufficient new directors

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas Biopharma Holdings Receives Non-Compliance Notice From NYSE American LLC

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 01, 2023

Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of Mat2203 in the IDSA Journal Clinical Infectious Diseases

Matinas BioPharma Holdings, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Consensus revenue estimates fall by 90%

Matinas BioPharma Holdings, Inc. to Report Q1, 2023 Results on May 10, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 46%

Forecast to breakeven in 2025

Price target decreased to US$2.75

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Matinas BioPharma Holdings, Inc. Announces Positive Interim Data from the Phase 2 EnACT Trial of MAT2203 for the Treatment of Cryptococcal Meningitis, Exceeding Primary Endpoint Threshold, Patient Survival in All-Oral Cohort 4 Regimen Currently 90%

Matinas BioPharma Holdings, Inc., Annual General Meeting, Nov 14, 2022

Matinas BioPharma Holdings, Inc. Announces Board Changes, Effective October 1, 2022

Consensus forecasts updated

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 41,381%

Price target decreased to US$2.75

Insufficient new directors

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

Insufficient new directors

Forecast to breakeven in 2024

Matinas Biopharma Announces Unanimous Dsmb Approval to Progress into Fourth and Final Cohort of Patients in the Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis

Matinas Biopharma Announces Positive Data in the Ongoing Enact Trial of Mat2203 for the Treatment of Cryptococcal Meningitis, Exceeding the Prespecified Primary Endpoint Threshold

Consensus forecasts updated

Consensus revenue estimates increase to US$2.48m

Forecast to breakeven in 2025

Consensus revenue estimates increase to US$1.27m

Full year 2020 earnings released: US$0.12 loss per share (vs US$0.13 loss in FY 2019)

Price target decreased to US$3.08

Here's Why We're Not Too Worried About Matinas BioPharma Holdings' (NYSEMKT:MTNB) Cash Burn Situation

Matinas BioPharma Announces Topline Results from ENHANCE-IT Study of LYPDISO™ Against Vascepa®

Price target raised to US$3.75

Matinas BioPharma Holdings, Inc. Announces FDA Conditional Acceptance of LYPDISO™ as the Brand Name for MAT9001

New 90-day high: US$1.47

Matinas Biopharma Holdings, Inc. Announces Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate Oral Formulations of Gilead’s Antiviral Remdesivir Utilizing Matinas LNC Platform Delivery Technology

Matinas BioPharma Holdings, Inc. Appoints Hui Liu as Chief Technology Officer

New 90-day high: US$0.90

Matinas BioPharma Holdings, Inc. Awards Up to $3.75 Million from the Cystic Fibrosis Foundation to Support Development of Oral Amikacin (MAT2501) for the Treatment of NTM Infections in Cystic Fibrosis Patients

Analysts increase revenue estimates to US$1.37m